MedTrace Logo

Maximum Treatment Interval With Aflibercept T&E

NCT05342857 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-04-25

No results posted yet for this study

Summary

To evaluate the duration of effectiveness of anti-VEGF (Aflibercept) by analyzing the percentage of patients whose maximum treatment interval is extended to 16 weeks and beyond in 24 months and their long-term remission.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

DRUG

Aflibercept Injection [Eylea]

Aflibercept 2.0 mg with the T\&E criteria in Taiwan local consensus

Sponsors & Collaborators

  • Shin Kong Wu Ho-Su Memorial Hospital

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-08-31
Completion
2025-04-30
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05342857 on ClinicalTrials.gov